AbbVie showcases breadth and depth of research in Crohn's disease and ulcerative colitis at UEG Week 2023.

AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (Skyrizi) and upadacitinib (Rinvoq in both Crohn's disease (CD) and ulcerative colitis (UC)..

Key data presentations will include : i. Research highlighting endoscopic outcomes with Skyrizi and Rinvoq for CD: a. LB01: Risankizumab versus ustekinumab for patients with moderate to severe Crohn's disease: results from the phase IIIb SEQUENCE study; Sunday, October 15, 17:00-17:12 CEST. b. OP100: Maintenance of clinical, endoscopic, and biomarker improvements with upadacitinib in patients with moderately to severely active Crohn's disease: a post hoc analysis of the phase III U-ENDURE study; Monday, October 16, 15:06-15:18 CEST. ii. Insights on long-term use with Rinvoq for UC: a. PP0853: Achievement of long-term treatment goals with upadacitinib in patients with moderately to severely active ulcerative colitis: a post-hoc analysis of induction and maintenance phase III trials; Sunday, October 15, 10:00 CEST.b. OP149: Efficacy and safety of upadacitinib after 2 years of treatment in patients with moderately to severely active ulcerative colitis: interim results from the phase III open-label extension study (U-ACTIVATE); Tuesday, October 17, 08:54-09:06 CEST. iii. Primary efficacy and safety results from the Phase III induction study for risankizumab in UC: a. OP021: Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase III INSPIRE study; Sunday, October 15, 17:48-18:00 CEST.